Minocycline, a semisynthetic tetracycline-derived antibiotic, has been shown to exert anti-apoptotic, anti-inflammatory, and antioxidant effects. Furthermore, there is rapidly growing evidence suggesting that minocycline may have some neuroprotective activity in various experimental models such as cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, Parkinson’s disease (PD), Huntington’s disease, and multiple sclerosis. In this perspective review, we summarize the preclinical and clinical findings suggesting the neuroprotective role of minocycline in PD.

**Keywords:** minocycline, neurodegeneration, neuroprotection, Parkinson’s disease.

**Citation**
Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B. The therapeutic role of minocycline in Parkinson’s disease. Drugs in Context 2019; 8: 212553. DOI: 10.7573/dic.212553

---

**Introduction**

Although the molecular cell death mechanisms involved in neurodegenerative diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD), are still not fully understood, progress in the knowledge of neuronal cell death in the common pathways has led to new approaches for neuroprotective therapies. The common pathways may include several pathogenic processes, such as energy (mitochondrial) impairment, secondary glutamate excitotoxicity, oxidative stress, and inflammatory mechanisms. Minocycline has been shown to exert its neuroprotective effect on common pathways in several neurodegenerative diseases, including PD. Among the neurodegenerative disorders, PD remains the only one that responds well to symptomatic therapy. Although levodopa treatment has been accepted as the gold standard of treatment, its chronic use is associated with potentially disabling motor complications. Furthermore, although it may improve some of the most disabling symptoms of PD, patients are faced with increased substantial disability over time and a future of dependency. In addition, there is no evidence that levodopa can halt or slow the progressive degeneration of dopaminergic (DA) neurons in the substantia nigra (SN). Moreover, there are controversial findings regarding the toxic actions of levodopa on the remaining dopaminergic neurons. Thus, there is a compelling need to develop treatments that might slow down the motor and nonmotor symptoms such as cognitive impairment in PD. Thus, one of the most important therapeutic needs in PD is the development of effective disease-modifying or neuroprotective therapies. In the light of these findings, researchers have spent an enormous effort to develop candidate neuroprotective agents for PD patients for the last 20 years. Recent findings of abnormal protein folding, coupled with oxidative stress and neuroinflammation, provide a scientific rationale for novel therapeutic strategies designed to slow disease progression in PD. In this context, recent research has been focused on the possible neuroprotective effects of anti-inflammatory drugs. So far, numerous studies, including the genetic, neurotoxic animal models, and clinical trials of minocycline in PD, have indicated that it may exert neuroprotective activity through inhibition of microglial activation, neuroinflammation, and neuronal apoptosis. Despite these promising results, no therapy has yet been proven to halt or slow disease progression of PD.

Minocycline has been chosen for this perspective review because of its capacity to decrease oxidative injury and neuroinflammation and so exert a potential neuroprotective activity, which has been proven in various in vivo and in vitro studies.
animal models. In this respect, our rationale was to evaluate minocycline’s neuroprotective effect in PD and to compare relevant studies, including clinical results, pathologic findings, and cognitive outcomes of minocycline. We have included retrospectively recorded results from animal studies, clinical trials, and also reviews in Medline via PubMed, Scopus, and ISI Web of Science. We used ‘Minocycline and Parkinson’s disease’, ‘minocycline and neuroprotection’, ‘minocycline’, and ‘neurodegeneration’ as key search items. From 292 potentially eligible reviews and studies, we selected 92 articles for full-text analysis.

**Minocycline**

Minocycline is a second-generation, semisynthetic tetracycline analogue, which is a highly lipophilic molecule and can easily penetrate the blood–brain barrier.9 It shows a better pharmacokinetic profile than the first-generation tetracyclines. However, it is rapidly and completely absorbed, even in elderly populations, with a longer half-life and excellent tissue penetration.10,11 In addition, it is a highly lipophilic molecule that can easily pass through the blood-brain barrier12, thus promoting its accumulation in the cerebrospinal fluid (CSF) and central nervous system (CNS)9,13,14 and enabling its use in the treatment of several CNS diseases.15–17 In rodents, minocycline readily crosses the blood-brain barrier with a rate of at least fivefold higher than doxycycline, another compound of the same family.18,19 Thereby, minocycline has been extensively studied in treating neurodegenerative diseases17,20,21 and has been reported to exert neuroprotective effects on various experimental models. These studies based on minocycline’s ability to inhibit microglia activation, which is a process that has deleterious effects on neurogenesis and neuronal survival could justify its potential effectiveness in the treatment of neuroinflammatory and/or neurodegenerative disorders.

**Mechanisms of action of minocycline**

Parkinsonian symptoms are caused by degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the consequent loss of their projecting nerve fibers in the striatum.22 Neuroinflammation and microglial activation, a hallmark of neuroinflammation that has been generally considered as an integral component of the progressive neurodegenerative process, has been increasingly implicated in the PD pathogenesis.23 It is noteworthy that minocycline is a potent inhibitor of microglial activation and of apoptotic pathways. Considering all of this evidence, it is not unreasonable to assume that minocycline exerts neuroprotective activity on animal models with PD via protecting the nigrostriatal pathway. Modes of actions of minocycline are summarized in Figure 1 and Box 1.

**The anti-inflammatory effect of minocycline**

Until now, studies have already indicated that neuroinflammation is mediated by microglia and astrocytes, which produce inflammatory cytokines, reactive oxygen species, and other toxic materials in the CNS.23 Here, reactive microgliosis, astrocytosis, an increase in proinflammatory mediators, and activation of inflammation-associated protein kinases are features common to many neurodegenerative disorders. For instance, a chronic release of proinflammatory cytokines by activating astrocytes and microglia leads to the exacerbation of DA neurons degeneration in the SNpc. These findings together suggest that microglia are one of the major cell types that are involved in the inflammatory response in the CNS. In parallel with that, it has been proposed that activated microglia may be beneficial to the host, at least in the early phase of the neurodegeneration process.26–28 The above-mentioned chronic neuroinflammation is also one of the hallmarks of PD pathophysiology. Beyond preclinical studies suggesting that there is a very similar chronic neuroinflammation process in PD, clinical data indicating the role of neuroinflammation are also rapidly replicating in PD.

Postmortem analyses of human PD patients indicate that the activation of glial cells and increases in proinflammatory factor levels are common features of the PD brain. However, long-term overactivation of microglia in the PD brain significantly upregulates the expression of a large group of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1 beta (β), and interferon gamma (IFN-γ), which contribute to the acceleration of nigral DA neuron degeneration.29–31

The main biological effects of minocycline, which are involved in the pathogenesis of several neurodegenerative disorders, include inhibition of microglial activation, attenuation of apoptosis, and suppression of reactive oxygen species (ROS) production. These effects appear completely different from its antimicrobial action.32 Minocycline exerts its neuroinflammatory actions by modulating microglia, immune cell activation, and subsequent release of cytokines, chemokines, lipid mediators of inflammation, MMPs, and NO release.33 Proinflammatory cytokines, such as TNF-α, IL-1β, and IL-6, are produced by microglial cells, astrocytes, neutrophils, and macrophages and augment both inflammation and following immune responses.33 Thus, any potential beneficial effects of minocycline in neurodegenerative diseases might well be exerted through its actions on the molecular pathways involving the modulation of one or more of these above-mentioned inflammatory factors.
**Figure 1.** Signaling mechanism involved in the neuroprotective actions of minocycline.

AIF, apoptosis-inducing factor; BCL-2, B-cell leukemia/lymphoma 2; CCR-5, chemokine receptor type 5; CXCR3, chemokine (CXC motif) receptor; GluR, glutamate receptor; IP-10, interferon-inducible protein; MAPK, mitogen-activated protein kinase; MIP-1α, macrophage inflammatory protein 1α; MMP, matrix metalloprotease; NADPH, nicotinamide-adenine dinucleotide phosphate; PBR, peripheral benzodiazepine receptor; TNF, tumor necrosis factor; TUNEL, terminal deoxynucleotidyl transferase dUTP (2’-deoxyuridine, 5’-triphosphate).
The therapeutic role of minocycline in Parkinson's disease

Tetracycline and its derivatives, especially minocycline, are a group of semisynthetic antibiotic agents that, besides their anti-inflammatory and antimicrobial properties, interfere with the activation of enzymes in the apoptotic pathway. Minocycline decreased apoptotic neuronal cell death observed under various experimental models of neurodegenerative diseases such as ischemia, HD, PD, AD, and ALS. This apoptotic effect is mainly being exerted on mitochondria. By reducing mitochondrial calcium overloading, minocycline stabilizes the mitochondrial membrane and inhibits release of cytochrome c and other apoptotic factors into the cytoplasm, which finally results with decreased caspase activation and nuclear damage that play a critical role in the apoptotic cell death cascade.

Furthermore, Caspase 8 activates a series of other caspases that finally lead to a series of lethal cleavages resulting in apoptosis (Figure 2). It has been revealed that B-cell leukemia/lymphoma 2 (Bcl-2), Bcl-2 family proteins, MAPK, mitogen-activated protein kinase; MMPs, matrix metalloprotease; mPT, mitochondrial permeability transition.

**Modes of action of minocycline.**

| **A. Anti-inflammatory actions** |
|-------------------------------|
| Modulation of microglia:       |
| - To reduce the proliferation/activation of resting microglial cells, subsequently decreasing the release of cytokines, chemokines, lipid mediators of inflammation, MMPs, and nitric oxide (NO) release |
| Alteration of immune cell activation: |
| - To inhibit transmigration of T lymphocytes |
| **B. Anti-apoptotic actions** |
| Caspase-dependent anti-apoptotic actions: |
| - Inhibition of cytochrome c release from mitochondria by attenuating mPT |
| - Inhibition of caspase-1 and -3 expression |
| Caspase-independent anti-apoptotic actions: |
| - Increase in the expression of Bcl-2 |
| - Inhibition of AIF release from mitochondria |

**C. Involvement in the signaling pathways**

Inhibition of p38 MAPK activation in microglia, thereby attenuating the production of IL-8, superoxide generation, and neutrophil chemotaxis

**Signaling pathways involved in minocycline’s neuroprotective actions**

Signaling mechanisms are also involved in the neuroprotective actions of minocycline. Minocycline shows its neuroprotective actions on p38 mitogen-activated protein kinase (MAPK)-dependent mechanism in the signaling pathway. P38 MAPKs are serine–threonine kinases that play significant roles in signaling for a vast number of cellular functions including cell migration, proliferation, and differentiation. It is initially identified as a stress-activated phosphorylated in response to inflammatory cytokines. The reduction effect of minocycline in p38 MAPK activities has inspired studies for validating minocycline’s neuroprotective effect.

It has been shown that minocycline increased neuronal survival in mixed spinal cord cultures, reduced NO-induced death of rats cerebellar granule neurons, and attenuated cell death by 50% in hypoxic-ischemic injury-induced death of a motor neuron cell line by reducing microglia activation through p38 MAPK-dependent mechanisms.

**The anti-apoptotic effect of minocycline**

A characteristic of many neurodegenerative diseases is neuronal cell death. Cell death occurs by necrosis or apoptosis. Although there were controversial data on the special cell death form of PD, recent studies support that apoptotic rather than the necrotic degeneration of dopaminergic cells in the SN plays a critical role in the pathogenesis of PD. Consistently, apoptosis has been demonstrated in the SN of postmortem brains of PD patients. Tetracycline and its derivatives, especially minocycline, are a group of semisynthetic antibiotic agents that, besides their anti-inflammatory and antimicrobial properties, interfere with the activation of enzymes in the apoptotic pathway. Minocycline decreased apoptotic neuronal cell death observed under various experimental models of neurodegenerative diseases such as ischemia, HD, PD, AD, and ALS. This apoptotic effect is mainly being exerted on mitochondria. By reducing mitochondrial calcium overloading, minocycline stabilizes the mitochondrial membrane and inhibits release of cytochrome c and other apoptotic factors into the cytoplasm, which finally results with decreased caspase activation and nuclear damage that play a critical role in the apoptotic cell death cascade.

In gerbils with global brain ischemia, minocycline increased the survival of hippocampal neurons and this protection was associated with reduced caspase-1 expression. Minocycline inhibits both caspase-dependent (cytochrome c and Smac/DIABLO) and caspase-independent anti-inflammatory...
activity in mitochondrial death pathways\textsuperscript{16} that is in line with its inhibitory effect on cytochrome c release, caspase-3 activation, and inflammation as shown by \textit{in vivo} and \textit{in vitro} models of HD and ALS.\textsuperscript{16,54}

Many studies have revealed that PD, cerebral ischemia, ALS, and HD share common pathophysiological pathways (i.e., oxidative injury, neuroinflammation) during the neurodegenerative process. As specifically mentioned earlier for the neuroprotective actions of minocycline, it has become a candidate for slowing or halting the degenerative process in the CNS.

**Minocycline and neuroprotection**

Yrjanheikki and colleagues first described minocycline as a neuroprotective agent that inhibits the ischemia-induced activation of microglia in an animal model of ischaemia.\textsuperscript{53} The neuroprotective role of minocycline was confirmed with further studies, which showed that minocycline inhibited neuronal death and reduced neurodegenerative disease progression including in different animal models such as PD, HD, MND, AD, and multiple sclerosis. For instance, in AD models, minocycline inhibited Aβ fibril formation,\textsuperscript{55} attenuated amyloid-induced microglial activation,\textsuperscript{56} and reduced the inflammatory events that were associated with the prevention of cognitive deficits.\textsuperscript{57} In line with this, minocycline also reduced the N-methyl D-aspartic acid (NMDA) toxicity in animal models of ischemic stroke\textsuperscript{35,58} and slowed the neurodegenerative progression in a mice model of HD.\textsuperscript{3,16,59} Unfortunately, despite promising results in experimental models of ALS,\textsuperscript{60,61} patients on minocycline declined more...
quickly than those on a placebo in clinical trials (phase III stage).\textsuperscript{62}

It should also be noted that a recent study has revealed that treatment with minocycline improved spatial memory in primates and rodents.\textsuperscript{66} The results of this clinical study were confirmed with a recent experimental study suggesting that minocycline enhanced the self-renewal capability of neural stem cells into the oligodendrocytes that were independent of its inhibitor effect on microglial activation in an autoimmune encephalomyelitis that is an animal model for multiple sclerosis.\textsuperscript{65} The neuroprotective and cognitive effects of minocycline in animal and human studies in PD have been summarized in Table 1.

### Neuroprotective effects of minocycline in animal models of Parkinson’s disease

Oxidative stress, mitochondrial dysfunction, inflammation, excitotoxicity, and abnormal processing of mutant proteins have played a critical role of the cell death of PD.\textsuperscript{62} Although the underlying mechanisms of the neuroprotective effect of minocycline are unclear, it is reasonable to assume that minocycline might exert its effect through an interactive signaling network including the mitochondria, oxidative stress, excitotoxicity, PARP-1, and apoptosis.\textsuperscript{42}

To reveal minocycline’s protective effects in PD, animal models with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are widely used. MPTP reproduces some of the basic PD features in primates and rodents. Thereby, it is regarded as a well-established model.\textsuperscript{66} In one MPTP model, minocycline treatment blocked dopamine depletion in the nucleus accumbens after MPTP administration.\textsuperscript{5}

### Table 1. Results of experimental studies on minocycline treatment for Parkinson’s disease.

| Study | Results |
|-------|---------|
| Du et al. (2001)\textsuperscript{5} | ↓MPTP-induced degeneration of DA neurons in the SNpc preventing loss of striatal DA and its metabolites ↓MPP+ mediated inducible NO synthase expression \textit{in vivo} and blocked NO-induced neurotoxicity \textit{in vitro} |
| Yi et al. (2001)\textsuperscript{80} | ↓Microglial activation and protection to tyrosine hydroxylase positive cells at 14 days after 6-OHDA injection. |
| Lin et al. (2001)\textsuperscript{36} | ↓p38 MAP kinase phosphorylation at 3 h by NO |
| Lin et al. (2003)\textsuperscript{105} | ↓6-OHDA-induced neuronal death in rat CGN |
| Yang et al. (2003)\textsuperscript{74} | ↑Neuron death, ↓microglial activation after MPTP in DA neurons \textit{in vitro} and \textit{in vivo} |
| Diguet et al. (2004)\textsuperscript{75} | ↑Severe/rapid parkinsonism, behavior deficits, and greater loss of nerve endings after MPTP in monkeys |
| Quintero et al (2006)\textsuperscript{106} | ↓The loss of tyrosine hydroxylase-immunoreactive cells in 6-OHDA-lesioned nigras in rats |
| Peng et al. (2006)\textsuperscript{107} | ↓Nigrostriatal dopaminergic neurodegeneration in murine mutant \textit{weaver} mouse \textit{in vivo} |
| McCoy et al. (2006)\textsuperscript{30} | ↓50% the retrograde nigral degeneration with neutralization of soluble TNF induced by a striatal injection of 6-OHDA \textit{in vivo} |
| Faust et al. (2009)\textsuperscript{108} | ↑DA neuroprotection in a \textit{Drosophila} model of PD and after rotenone toxicity in rodents |
| Radat et al. (2010)\textsuperscript{69} | ↓Neuron death after rotenone toxicity in embryonic mice |
| Bao-Ping Jiang et al. (2014)\textsuperscript{67} | ↓ICAD degradation and the NF-κB activation induced by 6-OHDA in pheochromocytoma (PC12) cells. |
| Cronin et al. (2017)\textsuperscript{70} | ↓Neuronal loss in a Zebrafish 6-OHDA model |

### Clinical Trials

| Study | Results |
|-------|---------|
| The NINDS NET-PD Investigators (2006)\textsuperscript{93,94} | Minocycline and creatine are futile in slowing down the progression of disability in PD at 12 months and 18 months. |

6-OHDA, 6-hydroxydopamine; CGN, cerebellar granule eurons; DA, dopaminergic neuron; ICAD, inhibitor of caspase-activated DNase; MAPK, mitogen-activated protein kinase; MPP+, 1-methyl-4-phenylpyridinium; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NET-PD, neuroprotective exploratory trials in Parkinson disease; NF-κB, nuclear factor kappa light chain enhancer of activated B cells; NINDS, National Institute of Neurological Disorders and Stroke; NO, nitric oxide; PD, Parkinson’s disease; SNpc, substantia nigra pars compacta.
The neuroprotective effect of minocycline was associated with marked reductions in inducible NO synthase (iNOS), caspase 1, mature interleukin-1, and the activation of NADPH–oxidase that are microglial-derived cytotoxic mediator expression.5 The same group has also shown that mutant iNOS-deficient mice treated with minocycline are more resistant to MPTP than iNOS-deficient mice not treated with minocycline.22 They commented the microglial-related inflammatory events’ crucial role in the MPTP neurotoxic process and suggested that minocycline may be a valuable neuroprotective agent for the treatment of PD.22 The neuroprotective effect of minocycline was also shown against the NO-induced phosphorylation of p38 mitogen-activated protein (MAP) kinase as well as the 6-hydroxydopamine (6-OHDA)-induced cell toxicity.67 Accordingly, the treatment of minocycline stimulated the differentiation of newly generated neuroblasts into mature striatal oligodendrocyte by increasing the activity of adult stem cells in a mice model of PD that suggested the possible role of oligodendrogenesis responsible for the behavioral improvements in the PD symptoms due to the increased stability and efficiency of axonal function.68

Additionally, minocycline was found to produce significant neuroprotection in primary dopaminergic cultures and zebrafish 6-OHDA model that was associated with the prevention and reversion of the locomotor deficits related to 6-OHDA.70

Minocycline’s protective effect on striatal dopamine loss was suggested with a different study model of SIV/macaque model of HIV-associated CNS disease showing that minocycline prevented striatal dopamine loss via elevated monoamine oxidase activity and antioxidative effect.71 In line with this, Eunju and colleagues have recently shown that minocycline also inhibited Prothrombin Kringle-2 (pKr-2) driven microglial activation in vivo. Similar antioxidant effects of minocycline have been also defined in oxidative impairment due to cypermethrin.72 The neuroprotective effects of minocycline were suggested following transgenic and MPTP studies including the Parkin null mutation and paraquat-induced mouse models.73 Despite these promising results, there are controversial preclinical data regarding the neuroproective effect of minocycline.

For instance, although minocycline inhibited microglial activation, minocycline significantly exacerbated MPTP-induced damage to DA neurons that is due to the inhibition of DA and 1-methyl-4-phenylpyridinium (MPP+) uptake into striatal vesicles. Additionally, Diguet and colleagues have shown the deleterious effect of minocycline on a mean motor score that was associated with impaired histopathologic outcomes in an MPTP mouse model of PD.75 It is difficult to estimate the cause of these inconsistent preclinical results; however, it can be hypothesized that different neurodegeneration and neuroinflammatory pathways could be responsible for failed positive minocycline study results in the literature. Despite these negative trials, minocycline has been proposed as a potential therapeutic agent for the treatment of neurodegenerative diseases due to its wide range of protective effects in different animal models of brain diseases.2,3,5,22,43,53,54,77

In line with this, the significant beneficial effects of minocycline on neuroinflammatory processes have been shown in PD (Table 2) as well as stroke animal models and in other neurodegenerative disease models.4,2,35,78–80

**Table 2. Neuroprotective effects of minocycline on pathological features of Parkinson’s disease.**

| Outcome | Animal | Outcome | Animal | Human |
|---------|--------|---------|--------|-------|
| ↑ Dopaminergic cell survival²² | + | Mitochondrial dysfunction and oxidative stress⁵,⁸³ | ↓ cytochrome c release and blocks apoptosis ↓ caspase 1 expression | – |
| ↓ Alpha-synuclein expression⁸⁴ | + | Neuroinflammation²² | Inhibits MPTP/6-OHDA and blocks microglial activation | – |
| ↑ GRP78 expression⁸⁵ | + | ↓ MPP+-induced apoptosis⁸⁶ | + | – |

6-OHDA, 6-hydroxy-dopamine; GRP78, glucose-regulated protein; MPP+, 1-methyl-4-phenylpyridinium, MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

**Procognitive effects of minocycline in animal models of Parkinson’s disease**

To the best of our knowledge, no study in the literature has evaluated cognitive outcomes in a PD animal model. As neuroinflammatory processes are implicated in neurodegenerative disorders characterized by prominent cognitive impairment, minocycline could be a promising candidate. Animal data would give us important clues regarding the possible procognitive effect of minocycline that is probably related to its anti-inflammatory effect through modulating the lipopolysaccharide (LPS).

It has been already revealed that LPS, a bacterial endotoxin, a commonly used inducer of neuroinflammation, can lead to cognitive impairment.⁸⁷ In this context, it is interesting to note that minocycline attenuates LPS-induced cognitive impairments in mice are associated with its action to suppress the neuroinflammation. From this point of view, it can be...
hypothesized that minocycline may normalize the activation of microglia astrocytes and brain-derived neurotrophic factor expression.\(^{87}\)

Additionally, in experimental models of LPS-induced neuroinflammation, minocycline reversed the nigral dopaminergic neuronal cell death and the loss of reactive astrocytes that were associated with improved cognitive outcomes.\(^{88,89}\)

Consistently, minocycline has been also shown to improve neurobehavioral deficits and cognitive decline in AD animal models that were related to the inhibition of neuroinflammatory markers, Aβ fibril formation, and NMDA toxicity.\(^{35,55,56,90}\) Agreeably, neuroinflammation, including reactive astrocytes and activated microglia, correlates with a serious cognitive decline and brain atrophy in AD.\(^{91,92}\)

**Neuroprotective effects of minocycline in clinical trials of Parkinson’s disease and Parkinson plus syndromes**

Several mechanisms of action have been proposed to be responsible for the neuroprotective effects of minocycline, which include the attenuation of microglial activation, apoptosis, and ROS production.

Regarding the neuroprotective properties of minocycline, the National Institute of Neurological Disorders and Stroke (NINDS) has aimed to identify potential agents to modify disease progression in PD. Through the Neuroprotective Exploratory Trials in Parkinson’s Disease (NET-PD) program, creatine and minocycline were used for the first study over 12 months (The NET-PD Futility Study 1, NET-PD FS-1).\(^{93}\)

Although there was evidence that both agents can protect against the dopaminergic neuronal loss associated with MPTP administration in a mouse model of PD, this study has failed to confirm the clinical neuroprotective effect of minocycline. An additional 6 months of follow up aimed to assess the safety and potential interactions of the study interventions with anti-Parkinsonian therapy (NET-PD FS-2). At the end of following up for 18 months, this phase II clinical study suggested that there was neither a beneficial effect nor an adverse event from using either creatine or minocycline in the treatment of PD. The authors commented that there was a need for a larger, phase III efficacy trial.\(^{94}\)

NET-PD investigators have also conducted a recent cohort-analysis to measure the disease progression in early PD through analyses an evaluation of progression-sensitive scales and questionnaires. Evaluating the effect of minocycline, creatine, Coenzyme Q10 and GPI-1485, a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands, and placebo in different control and patient groups, they have found no difference, neither in the minocycline group nor in the others regarding the primary indicator of disease progression that was defined as the time for starting a symptomatic pharmaceutical treatment.\(^{95}\)

The results of that study were in accordance with another study assessing the efficacy of minocycline in patients with Multiple System Atrophy-Parkinsonian subtype (MSA-P) that also revealed no symptomatic beneficial effects of minocycline in MSA-P.\(^{96}\)

Nowadays, there is still no randomized clinical minocycline therapy trial conducted on a massive scale.

**Possible procognitive effects of minocycline in clinical trials of Parkinson’s disease and Alzheimer’s disease**

Cognitive dysfunction is a common and significant nonmotor symptom of PD. PD mild cognitive impairment (PD-MCI) was defined in 2012 by the International Parkinson and Movement Disorder Society,\(^{97}\) and it has shown that approximately one-third of people have PD-MCI.\(^{98,99}\)

Longitudinal cohort studies have demonstrated that approximately half of the patients with PD for 10 years develop PD dementia (PDD),\(^{100}\) while the point prevalence of dementia among those with PD is roughly 30%.\(^{101}\) Although the underlying mechanisms of cognitive decline or dementia associated with PD remain unclear, it is believed that the presence of Lewy pathology within the limbic system and neocortex play a critical role in the impairment of cognition in PD. Lewy bodies are abnormal alpha-synuclein (α-syn) proteins, which are greatly responsible for the neurotoxicity via different mechanisms, including impairment of axonal transport, oxidative stress, mitochondrial changes, and synaptic dysfunction.\(^{102}\)

Despite increased understanding of pathology, neurotransmitter, and genetic drivers, there are no proven pharmacological treatments or protective agents for PD-MCI. Moreover, studies until now have shown that there is an only modest benefit for antidementia drugs that are licensed for PDD. These findings together suggest that there is an emerging need for a mechanism-based clinical treatment strategy for cognitive impairment in PD.\(^{103}\)

In this respect, it is worth to notice, that a new study, The minocycline in Alzheimer’s Disease Efficacy (MADE) study, is a multicenter, randomized, controlled trial in patients with very mild AD.\(^{104}\) Recruitment began in January 2014 and the trial ended in December 2017. It aimed to determine whether minocycline is effective in reducing the rate of cognitive and functional decline over a 2-year period and assess the safety and tolerability of minocycline. This multicenter, randomized double-blind placebo-controlled semifactorial (2×1) designed phase II clinical trial tested the efficacy and tolerability of 400 and 200 mg minocycline in disease modification of AD. There were 480 patients with very mild AD patients recruited
in England and Scotland. The patients were assessed with Standardized Mini-Mental State Examination and the Bristol Activities of Daily Living Scale.\textsuperscript{104} The results of the study have not been published yet.

**Conclusions**

Minocycline is a tetracycline that exerts antimicrobial, anti-inflammatory, anti-apoptotic, and antioxidant effects on the CNS.\textsuperscript{106} There is rapidly growing evidence showing that neurodegeneration and inflammation are fundamental aspects of many neurological diseases.\textsuperscript{109} In this respect, much attention has been focused on the potential use of currently available anti-inflammatory drugs to prevent neurodegeneration. In our perspective review, we have summarized various studies in animals and humans, which have confirmed beneficial effects and safety of minocycline, alone or combined with other drugs in PD.

**Contributions:** S Cankaya, B Cankaya and B Yulug were responsible for writing the article; E Kilic and U Kilic were responsible for revising the article; E Kilic and U Kilic carried out a language check of the article; S Cankaya and B Cankaya prepared the data for the article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

**Disclosure and potential conflicts of interest:** The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors are available for download at http://www.drugsincontext.com/wp-content/uploads/2019/02/dic.212553-COI.pdf

**Acknowledgments:** None.

**Funding declaration:** There is no funding for assisting this article for writing or studying.

**Copyright:** Copyright © 2019 Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.

**Correct attribution:** Copyright © 2019 Cankaya S, Cankaya B, Kilic U, Kilic E, Yulug B. https://doi.org/10.7573/dic.212553. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

**Article URL:** https://www.drugsincontext.com/the-therapeutic-role-of-minocycline-in-parkinsons-disease

**Correspondence:** Seyda Cankaya, Department of Neurology, Faculty of Medicine, Alaaddin Keykubat University, Alanya, Turkey. seyda.cankaya@alanya.edu.tr

**Provenance:** invited; externally peer reviewed.

**Submitted:** 9 August 2018; **Peer review comments to author:** 26 November 2018; **Revised manuscript received:** 20 January 2019; **Accepted:** 22 January 2019; **Publication date:** 6 March 2019.

**Drugs in Context** is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 9PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

**References**

1. Alexi T, Borlongan CV, Faull RL, et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s diseases. *Prog Neurobiol*. 2000;60(5):409–470. https://doi.org/10.1016/s0301-0082(99)00032-5
2. Seabrook TJ, Jiang L, Maier M, Lemere CA. Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg mice. *Glia*. 2006;53(7):776–782. https://doi.org/10.1002/glia.20338
3. Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. *Nat Med*. 2000;6(7):797–801. https://doi.org/10.1038/77528
4. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. *Neuroreport*. 2002;13(8):1067–1070. https://doi.org/10.1097/00001756-200206120-00018

5. Du Y, Ma Z, Lin S, et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson’s disease. *Proc Natl Acad Sci USA*. 2001;98(25):14669–14674. https://doi.org/10.1073/pnas.251341998

6. Lang AE. Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. *Nat Med*. 2010;16(11):1223–1226. https://doi.org/10.1038/nm.2220

7. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson’s disease? *Ann Neurol*. 2008;64 Suppl 2(S2):S510–S110. https://doi.org/10.1002/ana.21461

8. Olanow CW, Kieburtz K. Defining disease-modifying therapies for PD – a road map for moving forward. *Mov Disord*. 2010;25(12):1774–1779. https://doi.org/10.1002/mds.23288

9. Aronson AL. Pharmacotherapeutics of the newer tetracyclines. *J Am Vet Med Assoc*. 1980;176(10 Spec No):1061–1068. PubMed PMID: 7216873

10. Barza M, Brown RB, Shanks C, Gamble C, Weinstein L. Relation between lipophilicity and pharmacological behavior of minocycline, doxycycline, tetracycline, and oxytetracycline in dogs. *Antimicrob Agents Chemother*. 1975;8(6):713–720. https://doi.org/10.1128/aac.8.6.713

11. Klein NC, Cunha BA. Tetracyclines. *Med Clin North Am*. 1995;79(4):789–801. PubMed PMID: 7791423

12. Brogden RN, Speight TM, Avery G. Minocycline: a review of its antibacterial and pharmacological properties and therapeutic use. *Drugs*. 1975;9(4):251–291. PubMed PMID: 1173232

13. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. *Proc Natl Acad Sci USA*. 1999;96(23):13496–13500. https://doi.org/10.1073/pnas.96.23.13496

14. Kielian T, Esen N, Liu S, et al. Minocycline modulates neuroinflammation independently of its antimicrobial activity in staphylococcus aureus-induced brain abscess. *Am J Pathol*. 2007;171(4):1199–1214. https://doi.org/10.2353/ajpath.2007.070231

15. Saivin S, Houin G. Clinical pharmacokinetics of doxycycline and minocycline. *Clin Pharmacokinet*. 1988;15(6):355–366. https://doi.org/10.2165/00003088-198815060-00001

16. Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington’s disease. *Proc Natl Acad Sci USA*. 2003;100(18):10483–10487. https://doi.org/10.1073/pnas.1832501100

17. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. *Lancet Neurol*. 2004;3(12):744–751. https://doi.org/10.1016/S1474-4422(04)00937-8

18. Colovic M, Caccia S. Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. *J Chromatogr B*. 2003;791(1–2):337–343. https://doi.org/10.1016/S1570-0232(03)00247-2

19. Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington’s disease. *Ann Neurol*. 2003;54(2):186–196. https://doi.org/10.1002/ana.10614

20. Luccarini I, Ballerini C, Biagioli T, et al. Combined treatment with atorvastatin and minocycline suppresses severity of EAE. *Exp Neurol*. 2008;211(1):214–226. https://doi.org/10.1016/j.expneurol.2008.01.022

21. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. *J Am Acad Dermatol*. 2006;54(2):186–196. https://doi.org/10.1016/j.jaad.2005.10.004

22. Jackson-Lewis V, Vila M, Tieu K, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. *J Neurosci*. 2002;22(5):1763–1771. https://doi.org/10.1523/JNEUROSCI.22-05-01763.2002

23. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. *Neurology*. 2006;67(2):1285–1285. PubMed PMID: 1703952

24. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. *Behav Brain Res*. 2009;196(2):168–179. https://doi.org/10.1016/j.bbr.2008.09.040

25. Rogers J, Strohmeyer R, Kovelowski C, Li R. Microglia and inflammatory mechanisms in the clearance of amyloid β peptide. *Glia*. 2002;40(2):260–269. https://doi.org/10.1002/glia.10153

26. McGeer P, Itagaki S, Boys E, McGeer E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. *Neurology*. 1988;38(8):1285–1285. PubMed PMID: 3399080

27. Hu X, Li P, Guo Y, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. *Stroke*. 2012;43(1):3063–3070. https://doi.org/10.1161/STROKEAHA.112.659656

28. Cagnin A, Kassiou M, Meikle S, Banati R. In vivo evidence for microglial activation in neurodegenerative dementia. *Acta Neuropathol Scand*. 2006;114:107–114. https://doi.org/10.1111/j.1600-0404.2006.00694.x

29. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. *Transl Neurodegener*. 2015;4(1):19. https://doi.org/10.1186/s40035-015-0042-0
30. McCoy MK, Martinez TN, Ruhn KA, et al. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. *J Neurosci.* 2006;26(37):9365–9375. https://doi.org/10.1523/JNEUROSCI.1504-06.2006

31. Ferrari CC, Godoy MCP, Tarelli R, Chertoff M, Depino AM, Pitossi FJ. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1β in the substantia nigra. *Neurobiol Dis.* 2006;24(1):183–193. https://doi.org/10.1016/j.nbd.2006.01.013

32. Gabler WL, Smith J, Tsukuda N. Comparison of doxycycline and a chemically modified tetracycline inhibition of leukocyte functions. *Res Commun Chem Pathol Pharmacol.* 1992;78(2):151–160. PubMed PMID: 1335592

33. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. *Neuroscientist.* 2005;11(4):308–322. https://doi.org/10.1177/1073858405275175

34. Haines JD, Fragoso G, Hossain S, Mushynski WE, Almazan G. p38 Mitogen-activated protein kinase regulates myelination. *J Mol Neurosci.* 2008;35(1):23–33. https://doi.org/10.1007/s12031-007-9011-0

35. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. *J Immunol.* 2001;166(12):7527–7533. https://doi.org/10.4049/jimmunol.166.12.7527

36. Lin S, Zhang Y, Dodel R, Farlow MR, Paul SM, Du Y. Minocycline blocks nitric oxide-induced neurotoxicity by inhibition p38 MAP kinase in rat cerebellar granule neurons. *Neurosci Lett.* 2001;315(1–2):61–64. https://doi.org/10.1016/s0304-3900(01)02324-2

37. Guo G, Bhat NR, p38alpha MAP kinase mediates hypoxia-induced motor neuron cell death: a potential target of minocycline’s neuroprotective action. *Neurochem Res.* 2007;32(2):2160–2166. https://doi.org/10.1007/s11064-007-9408-8

38. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. *N Engl J Med.* 2003;348(14):1365–1375. https://doi.org/10.1056/NEJMra022366

39. Jellinger KA. Cell death mechanisms in neurodegeneration. *J Cell Mol Med.* 2001;5(1):1–17. https://doi.org/10.1111/j.1582-4934.2001.tb00134.x

40. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. *Exp Neurol.* 2000;166(1):29–43. https://doi.org/10.1006/exnr.2000.7489

41. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson’s disease. *J Neurol Sci.* 1996;137(2):120–123. https://doi.org/10.1016/0022-510x(95)00336-z

42. Thomas M, Le WD. Minocycline: neuroprotective mechanisms in Parkinson’s disease. *Curr Pharm Des.* 2004;10(6):679–686. https://doi.org/10.2174/1381612043453162

43. Choi Y, Kim HS, Shin KY, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer’s disease models. *Neuropsychopharmacology.* 2007;32(11):2393–2404. https://doi.org/10.1038/sj.npp.1301377

44. Stirling DP, Khodarahmi K, Liu J, et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. *J Neurosci.* 2004;24(9):2182–2190. https://doi.org/10.1523/JNEUROSCI.5275-03.2004

45. Garcia-Martinez EM, Sanz-Blasco S, Karachitos A, et al. Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. *Biochem Pharmacol.* 2010;79(2):239–250. https://doi.org/10.1016/j.bcp.2009.07.028

46. Antonenko YN, Rokitskaya TI, Cooper AJ, Krasnikov BF. Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria. *J Biol Chem.* 2001;276(17):15863–15871. https://doi.org/10.1074/jbc.M131629200

47. O Ulgen B, G Field M, Qureshi W, et al. The role of minocycline in ischemia-reperfusion injury: a comprehensive review of an old drug with new implications. *Recent Pat Cardiovasc Drug Discov.* 2011;6(2):123–132. https://doi.org/10.2174/157489011795393783

48. Filipovic R, Zecевич N. Neuroprotective role of minocycline in co-cultures of human fetal neurons and microglia. *Exp Neurol.* 2008;211(1):41–51. https://doi.org/10.1016/j.expneurol.2007.12.024

49. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science.* 2004;305(5684):626–629. https://doi.org/10.1126/science.1099302

50. Kroemer G. Mitochondrial control of apoptosis: an overview. *Biochem. Soc. Symp.* 1999;66(32):1–8. https://doi.org/10.1042/bss0660001

51. Wang J, Wei Q, Wang CY, Hill WD, Hess DC, Dong Z. Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria. *J Biol Chem.* 2004;279(19):19948–19954. https://doi.org/10.1074/jbc.M313629200

52. Castañeras M, Vera Y, Erkkila K, et al. Minocycline up-regulates BCL-2 levels in mitochondria and attenuates male germ cell apoptosis. *Biochem Biophys Res Commun.* 2005;337(2):663–669. https://doi.org/10.1016/j.bbrc.2005.09.101

53. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. *Proc Natl Acad Sci USA.* 1998;95(26):15769–15774. https://doi.org/10.1073/pnas.95.26.15769

54. Zhu S, Stavrovskaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. *Nature.* 2002;417(6884):47–78. https://doi.org/10.1038/417074a

55. Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid β fibril formation and human microglial activation. *Glia.* 2006;53(3):233–240. https://doi.org/10.1002/glia.20268
56. Fan R, Xu F, Previti ML, et al. Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci. 2007;27(12):3057–3063. https://doi.org/10.1523/JNEUROSCI.4371-06.2007

57. Parachikova A, Vasil'evko V, Cribbs DH, La Ferla FM, Green KN. Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis. 2010;21(2):527–542. https://doi.org/10.3233/JAD-2010-100204

58. Wang CX, Yang T, Shuaib A. Effects of minocycline alone and in combination with mild hypothermia in embolic stroke. Brain Res. 2003;963(1-2):327–329. https://doi.org/10.1016/S0006-8993(02)04045-3

59. Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease mice. Biochim Biophys Acta. 2006;1762(3):373–380. https://doi.org/10.1016/j.bbadi.2005.11.002

60. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13(8):1067–1070. https://doi.org/10.1097/00001756-200206120-00018

61. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10(3):268–278. https://doi.org/10.1006/nbdi.2002.0487

62. Traynor BJ, Brujin L, Convit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology. 2006;67(1):20–27. https://doi.org/10.1212/01.wnl.0000223353.34006.54

63. Garcez ML, Mina F, Bellettini-Santos T, et al. The Involvement of NLRP3 on the Effects of Minocycline in an AD-Like Pathology Induced by β-Amyloid Oligomers Administered to Mice. Mol Neurobiol. 2018:1–12. https://doi.org/10.1007/s12035-018-1211-9

64. Metz LM, DiK TB, Trapoulseal AL, et al. Trial of minocycline in a clinically isolated syndrome of multiple sclerosis. N Engl J Med. 2017;376(22):2122–2133. https://doi.org/10.1056/NEJMci1708486

65. Kuroda A, Fuchigami T, Fuke S, Ikenaka K, Hitoshi S. Minocycline directly enhances the self-renewal of adult neural precursor cells. Neurochem Res. 2018;43(1):219–226. https://doi.org/10.1007/s11064-017-2422-6

66. Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003;39(6):889–909. https://doi.org/10.1016/S0896-6273(03)00568-3

67. Jiang BP, Le L, Xu LJ, Xiao PG. Minocycline inhibits ICAD degradation and the NF-kappaB activation induced by 6-OHDA in PC12 cells. Brain Res. 2014;1586:1–11. https://doi.org/10.1016/j.brainres.2014.08.001

68. Worlitzer MM, Viel T, Jacobs AH, Schwamborn JC. The majority of newly generated cells in the adult mouse substantia nigra express low levels of Doublecortin, but their proliferation is unaffected by 6‐OHDA‐induced nigral lesion or Minocycline‐mediated inhibition of neuroinflammation. Eur J Neurosci. 2013;38(5):2684–2692. https://doi.org/10.1111/ene.12269

69. Radad K, Moldzio R, Rausch WD. Minocycline protects dopaminergic neurons against long-term rotenone toxicity. Can J Neurol Sci. 2010;37(1):81–85. https://doi.org/10.1016/S0317-1671(10)00096-0

70. Cronin A, Grealy M. Minocycline and Neuro-restorative Effects of Minocycline and Rasagiline in a Zebrafish 6-Hydroxydopamine Model of Parkinson’s Disease. Neuroscience. 2017;367:34–46. https://doi.org/10.1016/j.neuroscience.2017.10.018

71. Meulendyke KA, Pletnikov MV, Engle EL, Tarwater PM, Graham DR, Zink MC. Early minocycline treatment prevents a decrease in striatal dopamine in an SIV model of HIV-associated neurological disease. J Neuroimmune Pharmacol. 2012;7(2):454–464. https://doi.org/10.1016/j.jnph.2011.07.009

72. Tripathi P, Singh A, Agrawal S, Prakash O, Singh MP. Cypermethrin alters the status of oxidative stress in the peripheral blood: mediated inhibition of neuroinflammation. Eur J Neurosci. 2013;38(5):2684–2692. https://doi.org/10.1111/ene.12269

73. Diguet E, Fernagut PO, Wei X, et al. Minocycline inhibits mPTP toxicity to dopaminergic neurons. J Neurosci. 2003;23(4):1790–1800. https://doi.org/10.1038/nn.2009.3

74. Yang L, Sugama S, Chirichigno JW, et al. Minocycline enhances MFTP toxicity to dopaminergic neurons. J Neurosci. 2003;23(4):1790–1800. https://doi.org/10.1016/j.neuroscience.2006.05.043

75. Dehmer S, Przybylo AM, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. FASEB J. 2009;23(3):739–750. https://doi.org/10.1096/fj.08-113795

76. Ryu JK, Choi HB, McLarnon JG. Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington’s disease. Neuroscience. 2006;141(4):1835–1848. https://doi.org/10.1016/j.neuroscience.2006.05.043

77. Demmers M-A, Plaisant F, Verney C, Gressens P. Early microglial activation following neonatal excitotoxic brain damage in mice: a potential target for neuroprotection. Neuroscience. 2003;121(3):619–628. https://doi.org/10.1016/s0306-4522(03)00558-x

78. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001;909(1–2):187–193. https://doi.org/10.1006/sneu.2001.2681-6
82. Kilic U, Kilic E, Lingor P, Yulug B, Bahr M. Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. *Acta Neuropathol.* 2004;108(1):65–68. https://doi.org/10.1007/s00404-004-0867-6

83. Teng YD, Choi H, Onario RC, et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. *Proc Natl Acad Sci USA.* 2004;101(9):3071–3076. https://doi.org/10.1073/pnas.0306239101

84. Oida Y, Kitaichi K, Nakayama H, et al. Rifampicin attenuates the MPTP-induced neurotoxicity in mouse brain. *Brain Res.* 2006;1082(1):196–204. https://doi.org/10.1016/j.brainres.2006.01.116

85. Xu J, Wei C, Xu C, et al. Rifampicin protects PC12 cells against MPP+-induced apoptosis and inhibits the expression of an alpha-Synuclein multimer. *Brain Res.* 2007;1139:220–225. https://doi.org/10.1016/j.brainres.2006.12.074

86. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. Minocycline inhibits alpha-synuclein fibrillation and disaggregates fibrils. *Chem Biol.* 2004;11(1):1513–1521. https://doi.org/10.1016/j.chembiol.2004.08.025

87. Hou Y, Xie G, Liu X, et al. Minocycline protects against lipopolysaccharide-induced cognitive impairment in mice. *Psychopharmacology (Berl.)* 2016;233(5):905–916. https://doi.org/10.1007/s00213-015-4169-6

88. Kim WG, Mohney RP, Wilson B, Jeohn GH, Liu B, Hong JS. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *J Neurosci.* 2000;20(16):6309–6316. https://doi.org/10.1523/JNEUROSCI.20-16-06309.2000

89. Tomas-Camardiel M, Rite I, Herrera AJ, et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. *Neurobiol Dis.* 2004;16(1):190–201. https://doi.org/10.1016/j.nbd.2004.01.010

90. Biscaro B, Lindvall O, Tesco G, Ekdahl CT, Nitsch RM. Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer’s disease. *Neurodegener Dis.* 2012;9(4):187–198. https://doi.org/10.1159/000330363

91. McGeer PL, McGeer EG. Anti-inflammatory drugs in the fight against Alzheimer’s disease. *Ann NY Acad Sci.* 1996;777(1):213–220. https://doi.org/10.1111/j.1749-6632.1996.tb4421.x

92. Sokolova A, Hill MD, Rahimi F, Warden LA, Hallday GM, Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer’s disease. *Brain Pathol.* 2009;19(3):392–398. https://doi.org/10.1111/j.1750-3639.2008.00188.x

93. Investigators NN-P. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. *Neurology.* 2006;66(5):644–671. https://doi.org/10.1212/01.wnl.0000212522.57661.e1

94. Investigators NN-P. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. *Clin Neuropharmacol.* 2008;31(3):141–150. https://doi.org/10.1097/01.CNP.0000292071.63783.8e

95. Parashos SA, Luo S, Biglan KM, et al. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. *JAMA Neurol.* 2014;71(6):710–716. https://doi.org/10.1001/jamaneurol.2014.391

96. Dodel R, Spottke A, Gerhard A, et al. Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). *Mov Disord.* 2010;25(1):97–107. https://doi.org/10.1002/mds.22732

97. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. *Mov Disord.* 2012;27(3):349–356. https://doi.org/10.1002/mds.233421

98. Broeders M, De Bie R, Velseboer D, Speelman J, Muslimovic D, Schmand B. Evolution of mild cognitive impairment in Parkinson disease. *Neurology.* 2013;81(4):346–352. https://doi.org/10.1212/01.wnl.000033925c586

99. Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. *Neurology.* 2014;82(4):308–316. https://doi.org/10.1212/01.wnl.0000450816.97066.ee

100. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. *J Neural Neurosurg Psychiatry.* 2013;84(11):1258–1264. https://doi.org/10.1136/jnp-2013-305277

101. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. *Mov Disord.* 2005;20(10):1255–1263. https://doi.org/10.1002/mds.20527

102. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. *Nat Rev Neurosci.* 2013;14(9):626–636. https://doi.org/10.1038/nrn3549

103. Cosgrove J, Alty JE. Cognitive deficits in Parkinson’s disease: current perspectives. *J Parkinsonism Restless Legs Syndrome.* 2018;8:1–11. https://doi.org/10.2147/jprls.s125064

104. Howard R. Minocycline in Alzheimer’s disease efficacy trial: the MADE trial. https://gtr.ukri.org/projects?ref=MC_PC_13091. Accessed January 30, 2019.
105. Lin S, Wei X, Xu Y, et al. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. *Life Sci.* 2003;72(14):1635–1641. https://doi.org/10.1016/s0024-3205(02)02442-6

106. Quintero EM, Willis L, Singleton R, et al. Behavioral and morphological effects of minocycline in the 6-hydroxydopamine rat model of Parkinson’s disease. *Brain Res.* 2006;1093(1):198–207. https://doi.org/10.1016/j.brainres.2006.03.104

107. Peng J, Xie L, Stevenson FF, Melov S, Di Monte DA, Andersen JK. Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. *J Neurosci.* 2006;26(45):11644–11651. https://doi.org/10.1523/JNEUROSCI.3447-06.2006

108. Faust K, Gehrke S, Yang Y, Yang L, Beal MF, Lu B. Neuroprotective effects of compounds with antioxidant and anti-inflammatory properties in a Drosophila model of Parkinson’s disease. *BMC Neurosci.* 2009;10(1):109. https://doi.org/10.1186/1471-2202-10-109

109. Lidman O, Swanberg M, Horvath L, Broman KW, Olsson T, Piehl F. Discrete gene loci regulate neurodegeneration, lymphocyte infiltration, and major histocompatibility complex class II expression in the CNS. *J Neurosci.* 2003;23(30):9817–9823. https://doi.org/10.1523/JNEUROSCI.23-30-09817.2003

110. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. *JAMA.* 2004;291(3):358–364. https://doi.org/10.1001/jama.291.3.358

111. Noyes K, Liu H, Li Y, Holloway R, Dick AW. Economic burden associated with Parkinson’s disease on elderly Medicare beneficiaries. *Mov Disord.* 2006;21(3):362–372. https://doi.org/10.1002/mds.20727